These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://marvinmiti683089.ja-blog.com/39350904/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide